2017
DOI: 10.1111/bju.13722
|View full text |Cite
|
Sign up to set email alerts
|

Active surveillance in prostate cancer: new efforts, new voices, new hope

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 5 publications
0
1
0
Order By: Relevance
“…The occurrence of CRPC in PCa patients indicates that the median survival time of patients is likely to be <2 years. In addition, once the disease metastasizes, the median survival time of PCa is commonly <5 years 6,7. Therefore, investigating the molecular mechanism of PCa and seeking effective therapeutic targets remain pivotal in the hope of solving the current clinical issues in the treatment of PCa.…”
Section: Introductionmentioning
confidence: 99%
“…The occurrence of CRPC in PCa patients indicates that the median survival time of patients is likely to be <2 years. In addition, once the disease metastasizes, the median survival time of PCa is commonly <5 years 6,7. Therefore, investigating the molecular mechanism of PCa and seeking effective therapeutic targets remain pivotal in the hope of solving the current clinical issues in the treatment of PCa.…”
Section: Introductionmentioning
confidence: 99%